Clinical study of baricitinib in treating moderate to severe alopecia areata
Objective:To evaluate the efficacy and safety of baricitinib in the treatment of moderate to severe alopecia areata.Methods:Patients with moderate to severe alopecia areata(SALT≥25),whose responses to conventional treatment had failed,received baricitinib(2 mg/d,oral)(if the SALT score decreased by ≤20％after 12 weeks of medication compared to the base-line,the dosage increased to 4 mg/d).Patients were followed up at 4,12,and 24 weeks after treatment.The hair growth and adverse reactions at these time points were observed.Results:Forty-three patients completed a 24-week treatment,and the dose increased to 4 mg/d at week 12 in 13 patients.After 24 weeks of treatment,72.1％of the patients had hair covering more than 80％of the scalp,and 51.2％of the patients had an increase of ≥2 points in Investigator's Global Assessment(IGA)score from the baseline.No serious adverse reactions occurred.Conclusion:Baricitinib has good clinical efficacy and safety in the treatment of moderate to severe alopecia areata.
NETL
NSTL
万方数据
